Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.
Bavarian Nordic has licensed a cell line from Valneva to help it manufacture vaccines based on its modified vaccinia Ankara vaccine platform.
GlaxoSmithKline’s U.S. vaccine R&D head Ripley Ballou says emerging disease vaccine research needs a shakeup—and here's how.
The U.S. government is pumping more money into anthrax bioterror preparedness.
Protein Sciences will start the search for two new H7N9 vaccine candidates by request of the HHS’ Biomedical Advanced Research and Development Authority.
Astellas just forged a licensing deal with Affinivax to develop a pneumococcal vaccine. Their target? Pfizer’s Prevnar 13—the world’s best-selling vaccine.
Brazil’s health authority will expand its yellow fever vaccine stockpile by 11.5 million doses as an outbreak rages in the country. Previous outbreaks in…
Add PaxVax to the list of companies vying to put the first Chikungunya vaccine on the market.
Bristol-Myers and Bavarian Nordic kicked off testing of the Big Pharma's checkpoint inhibitor Opdivo alongside the biotech's cancer vaccine CV301 in…
The FDA has awarded a fast-track designation to Astellas’ peanut allergy vaccine candidate.